Dr David Collingridge is the Editor-in-Chief of The Lancet Oncology and the Publishing Director for The Lancet’s journals. Prior to his appointments at The Lancet, he gained a PhD in tumour biology from the Gray Cancer Institute/University College London, UK, and held research posts in the Department of Therapeutic Radiology, Yale University, CT, USA, and in the PET Oncology Group, Imperial College School of Medicine, London, UK.
Dr Collingridge has won awards for projects focused on cancer control in low-to-middle income countries; has published numerous peer-review articles, editorials, opinion pieces, and news reports; has co-authored a textbook on radiobiology; has been a contributor to various other books; and was previously a Clinical Associate Professor of Radiation Medicine at Hofstra/Northwell Health, Lake Success, NY, USA. He is currently a Visiting Professor of Global Oncology at King’s College London, UK.
Updated: September 2022